The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis
Mesalazine is an established and recommended first-line treatment for mild-to-moderate ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine or to initiate treatment with an oral corticosteroid or anti-tumor necrosis factor (TNF) agent is not clearly informed...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2024-06-01
|
| Sarja: | Frontiers in Gastroenterology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fgstr.2024.1335380/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|